Browsing by Author "Liu, Gin-Chung"

Now showing 1 - 13 of 13

Comparison of Gd-Bz-TTDA, Gd-EOB-DTPA, and Gd-BOPTA for dynamic MR imaging of the liver in rat models
(2012-03-01)
Jaw, Twei-Shiun
;
Chen, Shih-Hsien
;
Wang, Yun-Ming
;
Hsu, Jui-Sheng
;
Kuo, Yu-Ting
To evaluate the competitive potential of a new lipophilic paramagnetic complex, Gd-Bz-TTDA [4-benzyl-3,6,10-tri (carboxymethyl)-3,6,10-triazado-decanedioic acid] compared with two other commercially available MR hepatobiliary contrast agents, gadobenate dimeglumine (Gd-BOPTA) and gadoxetic acid (Gd-EOB-DTPA), dynamic MR imaging studies were performed on normal and hepatocellular carcinoma (HCC) rat models using a 1.5-Tesla MR scanner. The results indicate that normal rats that were injected with 0.1 mmol/kg Gd-Bz-TTDA showed significantly more intense and persistent liver enhancement than those that were injected with the same dose of Gd-EOB-DTPA or Gd-BOPTA. All of these agents showed similar enhancement patterns in the implanted HCC. The liver-lesion contrast-to-noise ratios were higher and more persistent in rats that were injected with Gd-Bz-TTDA. These results indicate that Gd-Bz-TTDA is comparable with the commercially available hepatobiliary agents, Gd-EOB-DTPA and Gd-BOPTA, and can result in more intense and prolonged liver enhancement while still providing better liver-lesion discrimination. These results warrant further large-scale studies. Copyright (C) 2012, Elsevier Taiwan LLC. All rights reserved.
Development of a Gd(III)-Based Receptor-Induced Magnetization Enhancement (RIME) Contrast Agent for beta-Glucuronidase Activity Profiling
(2012-11-19)
Chen, Shih-Hsien
;
Kuo, Yu-Ting
;
Singh, Gyan
;
Cheng, Tian-Lu
;
Su, Yu-Zheng
beta-Glucuronidase is a key lysosomal enzyme and is often overexpressed in necrotic tumor masses. We report here the synthesis of a pro receptor induced magnetization enhancement (pro RIME) magnetic resonance imaging (MRI) contrast agent ([Gd(DOTA-FP beta Gu)]) for molecular imaging of beta-glucuronidase activity in tumor tissues. The contrast agent consists of two parts, a gadolinium complex and a beta-glucuronidase substrate (beta-D-glucopyranuronic acid). The binding association constant (K-A) of [Gd(DOTA-FP beta Gu)] is 7.42 X 10(2), which is significantly lower than that of a commercially available MS-325 (K-A = 3.0 x 10(4)) RIME contrast agent. The low K-A value of [Gd(DOTA-FP beta Gu)] is due to the pendant beta-D-glucopyranuronic acid moiety. Therefore, [Gd(DOTA-FP beta Gu)] can be used for detection of beta-glucuronidase through RIME modulation. The detail mechanism of enzymatic activation of [Gd(DOTA-FP beta Gu)] was elucidated by LC-MS. The kinetics of beta-glucuronidase catalyzed hydrolysis of [Eu(DOTA-FP beta Gu)] at pH 7.4 best fit the Miechalis-Menten kinetic mode with K-m = 1.38 mM, K-cat = 3.76 x 10(3), and k(cat)/K-m = 2.72 x 10(3) M-1 s(-1). The low K-m value indicates high affinity of beta-glucuronidase for [Gd(DOTA-FP beta Gu)] FP beta Gu) at physiological pH. Relaxometric studies revealed that T-1 relaxivity of [Gd(DOTA-FP beta Gu)] changes in response to the concentration of beta-glucuronidase. Consistent with the relaxometric studies, [Gd(DOTA-FP beta Gu)] showed significant change in MR image signal in the presence of beta-glucuronidase and HSA. In vitro and in vivo MR images demonstrated appreciable differences in signal enhancement in the cell lines and tumor xenografts in accordance to their expression levels of beta-glucuronidase. [GRAPHICS] .
Development of Bifunctional Gadolinium-Labeled Superparamagnetic Nanoparticles (Gd-MnMEIO) for In Vivo MR Imaging of the Liver in an Animal Model
(2016-02-17)
Kuo, Yu-Ting
;
Chen, Chiao-Yun
;
Liu, Gin-Chung
;
Wang, Yun-Ming
;
生物科技學系
Liver tumors are common and imaging methods, particularly magnetic resonance imaging (MRI), play an important role in their non-invasive diagnosis. Previous studies have shown that detection of liver tumors can be improved by injection of two different MR contrast agents. Here, we developed a new contrast agent, Gd-manganese-doped magnetism-engineered iron oxide (Gd-MnMEIO), with enhancement effects on both T1-and T2-weighted MR images of the liver. A 3.0T clinical MR scanner equipped with transmit/receiver coil for mouse was used to obtain both T1-weighted spoiled gradient-echo and T2-weighted fast spin-echo axial images of the liver before and after intravenous contrast agent injection into Balb/c mice with and without tumors. After pre-contrast scanning, six mice per group were intravenously injected with 0.1 mmol/kg Gd-MnMEIO, or the control agents, i.e., Gd-DTPA or SPIO. The scanning time points for T1-weighted images were 0.5, 5, 10, 15, 20, 25, and 30 min after contrast administration. The post-enhanced T2-weighted images were then acquired immediately after T1-weighted acquisition. We found that T1-weighted images were positively enhanced by both Gd-DTPA and Gd-MnMEIO and negatively enhanced by SPIO. The enhancement by both Gd-DTPA and Gd-MnMEIO peaked at 0.5 min and gradually declined thereafter. Gd-MnMEIO (like Gd-DTPA) enhanced T1-weighted images and (like SPIO) T2-weighted images. Marked vascular enhancement was clearly visible on dynamic T1-weighted images with Gd-MnMEIO. In addition, the T2 signal was significantly decreased at 30 min after administration of Gd-MnMEIO. Whereas the effects of Gd-MnMEIO and SPIO on T2-weighted images were similar (p = 0.5824), those of Gd-MnMEIO and Gd-DTPA differed, with Gd-MnMEIO having a significant T2 contrast effect (p = 0.0086). Our study confirms the feasibility of synthesizing an MR contrast agent with both T1 and T2 shortening effects and using such an agent in vivo. This agent enables tumor detection and characterization in single liver MRI sections.
[Gd(Try-TTDA)(H(2)O)](2-): A new MRI contrast agent for copper ion sensing
(2011-01-01)
Kasala, Dayananda
;
Lin, Tsung-Sheng
;
Chen, Chiao-Yun
;
Liu, Gin-Chung
;
Kao, Chai-Lin
In this study, we have developed two new L-tryptophan based contrast agents [Gd(Try-TTDA)(H(2)O)](2-) and [Gd(Try-ac-DOTA)(H(2)O)](-). Upon addition of Cu(II) to [Gd(Try-TTDA)(H(2)O)](2-), significant increases in the relaxivity (r(1)) and hydration number of [Gd(Try-TTDA)(H(2)O)](2-) were observed. However, it only induced a minute increase in the relaxivity (r(1)) in the case of [Gd(Try-ac-DOTA)(H(2)O)](-). Furthermore, the interaction of Cu(II) with the indole ring of Gd(III) complexes was explored by measuring the intrinsic fluorescence of the tryptophan of the Gd(III) complex. With the addition of one equivalent of Cu(II) to [Gd(Try-TTDA)(H(2)O)](2) the indole fluorescence was completely quenched. Moreover, the [Gd(Try-TTDA)(H(2)O)](2-) complex shows excellent selectivity towards Cu(II) over other metal ions (Cu(II) > La(III) > Mg(II)). Importantly, the significant signal intensity (2073 +/- 67) for in vitro MR imaging using [Gd(Try-TTDA)(H(2)O)](2-) in the presence of Cu(II) implicates that this new smart contrast agent ([Gd(Try-TTDA)(H(2)O)](2-)) can serve as a Cu(II) sensor for MR imaging.
[Gd(Try-TTDA)(H2O)](2-): A new MRI contrast agent for copper ion sensing
(2011-01-01)
Kasala, Dayananda
;
Lin, Tsung-Sheng
;
Chen, Chiao-Yun
;
Liu, Gin-Chung
;
Kao, Chai-Lin
In this study, we have developed two new L-tryptophan based contrast agents [Gd(Try-TTDA)(H2O)](2-) and [Gd(Try-ac-DOTA)(H2O)](-). Upon addition of Cu(II) to [Gd(Try-TTDA)(H2O)](2-), significant increases in the relaxivity (r(1)) and hydration number of [Gd(Try-TTDA)(H2O)](2-) were observed. However, it only induced a minute increase in the relaxivity (r(1)) in the case of [Gd(Try-ac-DOTA)(H2O)](-). Furthermore, the interaction of Cu(II) with the indole ring of Gd(III) complexes was explored by measuring the intrinsic fluorescence of the tryptophan of the Gd(III) complex. With the addition of one equivalent of Cu(II) to [Gd(Try-TTDA)(H2O)](2) the indole fluorescence was completely quenched. Moreover, the [Gd(Try-TTDA)(H2O)](2-) complex shows excellent selectivity towards Cu(II) over other metal ions (Cu(II) > La(III) > Mg(II)). Importantly, the significant signal intensity (2073 +/- 67) for in vitro MR imaging using [Gd(Try-TTDA)(H2O)](2-) in the presence of Cu(II) implicates that this new smart contrast agent ([Gd(Try-TTDA)(H2O)](2-)) can serve as a Cu(II) sensor for MR imaging.
Imaging specificity of MR-optical imaging agents following the masking of surface charge by poly(ethylene glycol)
(2013-05-01)
Wu, Shou-Cheng
;
Lin, Kun-Liang
;
Wang, Tzu-Pin
;
Tzou, Shey-Cherng
;
Singh, Gyan
The coupling of specific antibodies to imaging agents often improves imaging specificity. However, free amine groups designed for the coupling can cause nonspecific binding of the imaging agents. We report here development of a nanocarrier, MnMEIO-silane-NH2-mPEG nanoparticles (NPs), consisting of a manganese-doped iron oxide nanoparticle core (MnMEIO), a copolymer shell of silane and amine-functionalized poly(ethylene glycol) (silane-EA-mPEG). The key feature in MnMEIO-silane-NH2-mPEG is the flexible PEG, which masks the non-conjugated reactive amine groups (-NH2 <-> -NH3+) and reduces nonspecific binding of MnMEIO-silane-NH2-mPEG to cells. The amine groups on MnMEIO-silane-NH2-mPEG were conjugated with the fluorescent dye, Cy777 or antibodies [Erbitux (Erb)] to form a MR-optical imaging contrast agent (MnMEIO-silane-NH2-(Erb)-mPEG) for EGFR-expressing tumors. Confocal microscopic and flow cytometric analyses showed that MnMEIO-silane-NH2-(Erb)-mPEG displayed low nonspecific binding. Moreover, TEM images showed that MnMEIO-silane-NH2-(Erb)-mPEG were endocytosed by EGFR-expressing cells. In line with their EGFR expression levels, A431, PC-3, and Colo-205 tumors treated with MnMEIO-silane-NH2-(Erb)-mPEG NPs showed -97.1%, -49.7%, and -2.8% contrast enhancement, respectively, in in vitro T-2-weighted MR imaging. In vivo T-2-weighted MR imaging and optical images showed that MnMEIO-silane-NH2-(Erb)mPEG could specifically and effectively target to EGFR-expressing tumors in nude mice; the relative contrast enhancements were 7.94 (at 2 h) and 7.59 (at 24 h) fold higher in A431 tumors as compared to the EGFR-negative Colo-205 tumors. On the contrary, MnMEIO-silane-NH2-(Erb) NPs showed only 1.44 (at 2 h) and 1.52 (at 24 h) fold higher in EGFR-positive tumors as compared to the EGFR-negative tumors. Finally, antibodies can be readily changed to allow imaging of other tumors bearing different antigens. These data indicate that masking surface charges on contrast agents is a useful strategy to improve imaging efficacy. (c) 2013 Elsevier Ltd. All rights reserved.
In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent
(2013-05-01)
Chen, Shih-Hsien
;
Kuo, Yu-Ting
;
Cheng, Tian-Lu
;
Chen, Chiao-Yun
;
Chiu, Yen-Yu
We compared the enhancement effect between a newly synthesized tissue-specific contrast agent, [Gd-DOTA-FP beta G], and a commercially available agent, [Gd(DOTA)](-), in a murine model of liver tumor using a clinical magnetic resonance imaging scanner. The colon cancer cell lines with and without beta-glucuronidase (beta G) expression were implanted into the liver of mice. Self-synthesized gadolinium-based magnetic resonance contrast agent, [Gd(DOTA-FP beta G)], was administered to measure enhancement on magnetic resonance images using a commercially available agent, [Gd(DOTA)](-), as control in a clinical 3.0 tesla (T) magnetic resonance scanner. In vivo fluorescence imaging and histopathology of the liver were also performed to compare and correlate with the magnetic resonance studies. The in vivo fluorescence imaging failed to depict a sufficiently intense signal for liver or liver tumor of mice without exposure of the liver following an incision on the abdominal wall. The tissue-specific magnetic resonance agent, [Gd(DOTA-FP beta G)], caused significantly stronger enhancement in tumors expressing beta G (CT26/m beta G-eB7) than in tumors not expressing beta G (CT26) (p < 0.05). In the magnetic resonance imaging studies using control agent [Gd(DOTA)](-), the tumors with and without beta G expression depicted no significant difference in enhancement on the T1-weighted images. The [Gd(DOTA-FP beta G)] also provided significantly more contrast uptake in the CT26/m beta G-eB7 tumor than in the normal liver parenchyma, whereas the [Gd(DOTA)](-) did not. This study confirms that better contrast enhancement can be readily detected in vivo by the use of a tissue-specific magnetic resonance contrast agent to target tumor cells with specific biomarkers in a clinical magnetic resonance imaging scanner. Copyright (c) 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5
(2011-02-01)
Lin, Ying-Hsiu
;
Dayananda, Kasala
;
Chen, Chiao-Yun
;
Liu, Gin-Chung
;
Luo, Tsai-Yueh
Magnetic resonance imaging (MRI) has become the leading imaging tool for providing fine anatomical and physiology details. Optical imaging is offering a sensitive and specific method for in vivo molecular imaging of targeting molecules. The goal of this study is to design, synthesize, and characterize a new target-specific dual contrast agent for MR and optical imaging. Hence, [Gd(TTDA-NP)(H(2)O)](2-) was prepared and characterized. In addition, an 8-amino acid Bombesin analogue (BN) peptide substrate, which can target prostate, breast, and colon cancer, was synthesized by solid-phase peptide synthesis and subsequently conjugated with [Gd(TTDA-NP)(H(2)O)](2-) to form BN conjugated Gd-TTDA-NP-BN. The water-exchange rate (ke(ex)(298)) for [Gd(TTDA-NP)(H(2)O)](2-) (110 x 10(6) s(-1)) is significantly higher than that of [Gd(DTPA) (H(2)O)](2-) complex and the rotational correlation time (tau(R)) for [Gd(TTDA-NP)(H(2)O)](2-) (145 ps) is also higher than those of [Gd(TTDA)(H(2)O)](2-) (104 ps) and [Gd(DTPA)(H(2)O)](2-) (103 ps). The Gd-TTDA-NP-BN shows remarkable high relaxivity (7.12 mM(-1) s(-1)) comparing to that of [Gd(TTDA-NP)(H(2)O)](2-). The fluorescence studies showed that the Gd-TTDA-NP-BN could efficiently enter PC-3 cells. Additionally, the human cancer cells xenografts using Gd-TTDA-NP-BN-Cy5.5 as an optical imaging probe clearly visualized subcutaneous PC-3 tumor and demonstrated its targeting ability to the gastrin releasing peptide (GRP) receptor overexpression. Furthermore, the biodistribution studies demonstrated significantly high tumor uptake (25.97 +/- 1.07% ID/g) and high tumor-to-normal tissue ratios at one hour post-injection of Gd-TTDA-NP-BN-Cy5.5 in the animal model. These results suggest that the Gd-1TDA-NP-BN-Cy5.5 is a superior probe for in vivo optical imaging. Importantly, the MR imaging studies showed notable signal enhancement (44.9 +/- 4.2%) on the tumor, indicating a high level accumulation of the contrast agent within the PC-3 tumor sites. Hence, targeting of prostate cancer cells was observed under in vitro and in vivo MR imaging studies using Gd-TTDA-NP-BN contrast agent. We conclude that Gd-TTDA-NP-BN and Gd-TTDA-NP-BN-Cy5.5 can be potentially used as the contrast agents for targeting GRP receptor oyerexpressing cells and tumors. (C) 2010 Elsevier Ltd. All rights reserved.
Synthesis and Physicochemical Characterization of Carbon Backbone Modified [Gd(TTDA)(H(2)O)](2-) Derivatives
(2011-02-21)
Chang, Ya-Hui
;
Chen, Chiao-Yun
;
Singh, Gyan
;
Chen, Hsing-Yin
;
Liu, Gin-Chung
The present study was designed to exploit optimum lipophilicity and high water-exchange rate (k(ex)) on low molecular weight Gd(III) complexs to generate high bound relaxivity (r(1)(b)), upon binding to the lipophilic site of human serum albumin (HSA). Two new carbon backbone modified TTDA (3,6,10-tri(carboxymethyl)-3,6,10-triazadodecanedioic acid) derivatives, CB-TTDA and Bz-CB-TTDA, were synthesized. The complexes [Gd(CB-TTDA)(H(2)O)](2-) and [Gd(Bz-CB-TTDA)(H(2)O)](2-) both display high stability constant (log K(GdL) = 20.28 and 20.09, respectively). Furthermore, CB-TTDA (log K((Gd/Zn)) = 4.22) and Bz-CB-TTDA (log K((Gd/Zn)) = 4.12) exhibit superior selectivity of Gd(III) against Zn(II) than those of TTDA (log K((Gd/Zn)) = 2.93), EPTPA-bz-NO(2) (log K((Gd/Zn)) = 3.19), and DTPA (log K((Gd/Zn)) = 3.76). However, the stability constant values of [Gd(CB-TTDA)(H(2)O)](2-) and [Gd(Bz-CB-TTDA)(H(2)O)](2-) are lower than that of MS-325. The parameters that affect proton relaxivity have been determined in a combined variable temperature (17)O NMR and NMRD study. The water exchange rates are comparable for the two complexes, 232 x 10(6) s(-1) for [Gd(CB-TTDA)(H(2)O)](2-) and 271 x 10(6) s(-1) for [Gd(Bz-CB-TTDA)(H(2)O)](2-). They are higher than those of [Gd(TTDA)(H(2)O)](2-) (146 x 10(6) s(-1)), [Gd(DTPA)(H(2)O)](2-) (4.1 x 10(6) s(-1)), and MS-325 (6.1 x 10(6) s(-1)). Elevated stability and water exchange rate indicate that the presence of cyclobutyl on the carbon backbone imparts rigidity and steric constraint to [Gd(CB-TTDA)(H(2)O)](2-) and [Gd(Bz-CB-TTDA)(H(2)O)](2-). In addition, the major objective for selecting the cyclobutyl is to tune the lipophilicity of [Gd(Bz-CB-TTDA)(H(2)O)](2-). The binding affinity of [Gd(Bz-CB-TTDA)(H(2)O)](2-) to HSA was evaluated by ultrafiltration study across a membrane with a 30 kDa MW cutoff, and the first three stepwise binding constants were determined by fitting the data to a stoichiometric model. The binding association constants (K(A)) for [Gd(CB-TTDA)(H(2)O)](2-) and [Gd(Bz-CB-TTDA)(H(2)O)](2-) are 1.1 x 10(2) and 1.5 x 10(3), respectively. Although the K(A) value for [Gd(Bz-CB-TTDA)(H(2)O)](2-) is lower than that of MS-325 (K(A) = 3.0 x 10(4)), the r(1)(b) value, r(1)(b) = 66.7 mM(-1) s(-1) for [Gd(Bz-CB-TTDA)(H(2)O)](2-), is significantly higher than that of MS-325 (r(1)(b) = 47.0 mM(-1) s(-1)). As measured by the Zn(II) transmetalation process, the kinetic stabilities of [Gd(CB-TTDA)(H(2)O)](2-), [Gd(Bz-CB-TTDA)(H(2)O)](2-), and [Gd(DTPA)(H(2)O)](2-) are similar and are significantly higher than that of [Gd(DTPA-BMA)(H(2)O)](2-) High thermodynamic and kinetic stability and optimized lipophilicity of [Gd(CB-TTDA)(H(2)O)](2-) make it a favorable blood pool contrast agent for MRI.
Synthesis and Physicochemical Characterization of Carbon Backbone Modified [Gd(TTDA)(H2O)](2-) Derivatives
(2011-02-21)
Chang, Ya-Hui
;
Chen, Chiao-Yun
;
Singh, Gyan
;
Chen, Hsing-Yin
;
Liu, Gin-Chung
The present study was designed to exploit optimum lipophilicity and high water-exchange rate (k(ex)) on low molecular weight Gd(III) complexs to generate high bound relaxivity (r(1)(b)), upon binding to the lipophilic site of human serum albumin (HSA). Two new carbon backbone modified TTDA (3,6,10-tri(carboxymethyl)-3,6,10-triazadodecanedioic acid) derivatives, CB-TTDA and Bz-CB-TTDA, were synthesized. The complexes [Gd(CB-TTDA)(H2O)](2-) and [Gd(Bz-CB-TTDA)(H2O)](2-) both display high stability constant (log K-GdL = 20.28 and 20.09, respectively). Furthermore, CB-TTDA (log K-(Gd/Zn) = 4.22) and Bz-CB-TTDA (log K-(Gd/Zn) = 4.12) exhibit superior selectivity of Gd(III) against Zn(II) than those of TTDA (log K-(Gd/Zn) = 2.93), EPTPA-bz-NO2 (log K-(Gd/Zn) = 3.19), and DTPA (log K-(Gd/Zn) = 3.76). However, the stability constant values of [Gd(CB-TTDA)(H2O)](2-) and [Gd(Bz-CB-TTDA)(H2O)](2-) are lower than that of MS-325. The parameters that affect proton relaxivity have been determined in a combined variable temperature O-17 NMR and NMRD study. The water exchange rates are comparable for the two complexes, 232 x 10(6) s(-1) for [Gd(CB-TTDA)(H2O)](2-) and 271 x 10(6) s(-1) for [Gd(Bz-CB-TTDA)(H2O)](2-). They are higher than those of [Gd(TTDA)(H2O)](2-) (146 x 10(6) s(-1)), [Gd(DTPA)(H2O)](2-) (4.1 x 10(6) s(-1)), and MS-325 (6.1 x 10(6) s(-1)). Elevated stability and water exchange rate indicate that the presence of cyclobutyl on the carbon backbone imparts rigidity and steric constraint to [Gd(CB-TTDA)(H2O)](2-) and [Gd(Bz-CB-TTDA)(H2O)](2-). In addition, the major objective for selecting the cyclobutyl is to tune the lipophilicity of [Gd(Bz-CB-TTDA)(H2O)](2-). The binding affinity of [Gd(Bz-CB-TTDA)(H2O)](2-) to HSA was evaluated by ultrafiltration study across a membrane with a 30 kDa MW cutoff, and the first three stepwise binding constants were determined by fitting the data to a stoichiometric model. The binding association constants (K-A) for [Gd(CB-TTDA)(H2O)](2-) and [Gd(Bz-CB-TTDA)(H2O)](2-) are 1.1 x 10(2) and 1.5 x 10(3), respectively. Although the K-A value for [Gd(Bz-CB-TTDA)(H2O)](2-) is lower than that of MS-325 (K-A = 3.0 x 10(4)), the r(1)(b) value, r(1)(b) = 66.7 mM(-1) s(-1) for [Gd(Bz-CB-TTDA)(H2O)](2-), is significantly higher than that of MS-325 (r(1)(b) = 47.0 mM(-1) s(-1)). As measured by the Zn(II) transmetalation process, the kinetic stabilities of [Gd(CB-TTDA)(H2O)](2-), [Gd(Bz-CB-TTDA)(H2O)](2-), and [Gd(DTPA)(H2O)](2-) are similar and are significantly higher than that of [Gd(DTPA-BMA)(H2O)](2-) High thermodynamic and kinetic stability and optimized lipophilicity of [Gd(CB-TTDA)(H2O)](2-) make it a favorable blood pool contrast agent for MRI.
Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI
(2009-02-01)
Chen, Ting-Jung
;
Cheng, Tsan-Hwang
;
Chen, Chiao-Yun
;
Hsu, Sodio C. N.
;
Cheng, Tian-Lu
A novel magnetic resonance imaging (MRI) contrast agent containing Herceptin is reported. The surfaces of superparamagnetic iron oxide nanoparticles were modified with dextran and conjugated with Herceptin (Herceptin-nanoparticles) to improve their dispersion, magnetization, and targeting of the specific receptors on cells. From analytical results, we found that Herceptin nanoparticles were well dispersed in solutions of various pH range, and had no hysteresis, high saturation magnetization ( 80 emu/g), and low cytotoxicity to a variety of cells. Notably, the magnetic resonance enhancements for the different breast cancer cell lines (BT-474, SKBR-3, MDA-MB-231, and MCF-7) are proportional to the HER2/neu expression level in vitro. When Herceptin-nanoparticles were administered to mice bearing breast tumor allograft by intravenous injection, the tumor site was detected in T(2)-weighted magnetic resonance images as a 45% enhancement drop, indicating a high level of accumulation of the contrast agent within the tumor sites. Therefore, targeting of cancer cells was observed by in vitro and in vivo MRI studies using Herceptin-nanoparticles contrast agent. In addition, Herceptin-nanoparticles enhancing the magnetic resonance signal intensity were sufficient to detect the cell lines with a low level of HER2/neu expression.
Targeted RGD nanoparticles for highly sensitive in vivo integrin receptor imaging
(2012-01-01)
Lin, Ren-Yen
;
Dayananda, Kasala
;
Chen, Ting-Jung
;
Chen, Chiao-Yun
;
Liu, Gin-Chung
A new magnetic resonance imaging (MRI) contrast bearing RGD peptide is reported. In this study, ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles with various sizes were prepared. Particles sizes between 6 and 13?nm were tuned by varying the stirring rate. Remarkable negative contrast was observed because USPIO nanoparticles (13.1?+/-?2.1?nm) generated high transversal relaxivity r2 (188?+/-?3?m m-1?s-1) and saturation magnetization (94?emu?g-1 Fe). The USPIO nanoparticles were coated with PDA [2-(pyridyldithio)-ethylamine; PDA nanoparticles] containing functional polymer, which can be readily synthesized by Michael addition. The PDA nanoparticles were conjugated with RGD peptide (RGD nanoparticles) for targeting the specific site. The target specificity and high relaxivity allowed RGD nanoparticles to differentiate the expression level of integrin receptor on several cell lines and tumors (MCF-7, A-549, HT-29 and HT-1080) by in vitro and in vivo MR imaging. Importantly, a remarkable negative contrast (-51.3?+/-?6.7%) was observed for in vivo MR imaging of MCF-7 tumor. This result implies that the RGD nanoparticles that greatly enhance the MR imaging are highly sensitive for early stage tumor detection. Copyright (c) 2012 John Wiley & Sons, Ltd.
The Imaging Behavior of an MRI Contrast Agent [Gd(TTDA-BOM)](2-) in a Mice Liver Tumor Model at 3 Tesla
(2010)
Jao, Jo-Chi
;
Lu, Hsiang-Chin
;
Lu, Hsin-Ying
;
Wang, Yun-Ming
;
Liu, Gin-Chung
[Gd(TTDA-BOM)](2-) is a newly developed paramagnetic contrast agent. The aim of this study was to investigate the magnetic resonance imaging (MRI) behavior of [Gd(TTDA-BOM)](2-) in mice with implanted AS-30D (Chang hepatoma ascites, CHA) tumor in liver at a 3T high-field whole-body magnetic resonance (MR) scanner. The high-field MR scanner is expected to have a higher signal-to-noise ratio (SNR). The dynamic MRI studies show that the signal enhancement in liver is larger than that in tumor, so that the contrast-to-noise ratio (CNR) between liver and tumor increases after [Gd(TTDA-BOM)](2-) injection. During one-hour investigation, it was found that [Gd(TTDA-BOM)](2-) could stay in liver up to one hour. On the contrary, [Gd(DTPA)](2-) , a kind of commercial contrast agent, was excreted from liver quickly. Therefore, the CNR between liver and tumor using [Gd(TTDA-BOM)](2-) is larger than that using [Gd(DTPA)](2-) and remains high at least up to one hour. In conclusion, [Gd(TTDA-BOM)](2-) might have good potential for being a hepatobiliary MR contrast agent.